For the most up-to-date news and information on the coronavirus pandemic, visit the who other Centers for Disease Control and Prevention websites.
An advisory panel to the US Food and Drug Administration Thursday voted to recommend a booster shot from Modern COVID-19 vaccine for many Americans, at least six months after their second dose.
The panel voted unanimously in favor of a half-dose injection for people over 65, people over 18 at high risk for severe COVID-19, and people over 18 whose jobs put them at risk for COVID-19 infection. 19. These are the same groups that became eligible for a Pfizer booster last month.
the COVID-19 vaccines are highly effective in the prevention of hospitalization and death. During the summer, when the delta variant took hold in the US, the number of COVID-19 cases, hospitalizations and deaths increased. Those who are not vaccinated have counted almost all hospitalizations and deaths – more than 97% as of July.
While the US already offers a Pfizer vaccine booster shot for some people, only 2.5% of people living in low-income countries You have received at least one dose of vaccine.
The FDA panel’s vote is not binding, but the agency will likely accept the recommendation. FDA approved Pfizer’s booster vaccine less than a week after an advisory panel made its recommendation.
The FDA has already granted an emergency authorization for a third dose of Moderna vaccine for some immunosuppressed adults.
The panel will meet again on Friday to discuss a booster dose for Johnson & Johnson’s COVID-19 vaccine.